EURYCOMANONE

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Eurycomanone 通过上调 p53 和 Bax 以及下调 Bcl-2 诱导细胞凋亡，对 HepG2 细胞具有细胞毒性。

Eurycomanone is cytotoxic on HepG2 cells by inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2.Eurycomanone has anti-cancer activity, inhibits A549 lung cancer cell proliferation in a dose-dependent manner at concentrations ranging from 5 to 20 μg/ml.

Eurycomanone (EN) significantly increased testosterone production dose-dependently at 0.1, 1.0 and 10.0 μM, but the two lower doses when combined with 3-isobutyl-1-methylxanthine (IBMX), the phosphodiesterase inhibitor were not significantly higher than EN or IBMX alone, except at a higher concentration. The molecular docking studies indicated EN and IBMX were binding at different sites of the enzyme. EN has no reversal of inhibition by aminoglutethimide, ketoconazole or nifedipine at the respective steroid oogenesis enzyme. The quassinoid was also non-responsive to the inhibition of oestrogen receptor by tamoxifen, but displayed improved for mestane inhibition of aromatase in reducing oestrogen production. The molecular docking studies further supported that EN and formestane bound to aromatase with similar orientations and free energy binding values.

——

——

Others

Other Targets

——

——

——

84633-29-4

444.43

C20H28O11

>98% (HPLC)

In Vitro:?DMSO : 16.67 mg/mL (40.82 mM)

CC1=CC(=O)[C@H]([C@]2([C@H]1C[C@@H]3[C@]45[C@@H]2[C@]([C@@H](C(=C)[C@@]4([C@H](C(=O)O3)O)O)O)(OC5)O)C)O

——

(-20℃)

With Ice Pack

≥ 2 years